Search Clinical Trials
Completed
Peer-led Group Intervention for Coping With Disaster (External Link)
Approximately 20% of individuals have significant behavioral health concerns. Exposure to a disaster like Hurricane Harvey and its aftermath often exacerbates pre-existing issues and/or brings new issues, with post-traumatic stress …
Baylor Role:
Lead Sponsor
Completed
Maternal Mental Health in the Hospital Setting (External Link)
Study participants will complete a survey about their general needs and access to resources and a survey to screen for postpartum depression to determine if the participant will be enrolled. …
Completed
Study to Treat Major Depressive Disorder With a New Medication (External Link)
Depressive disorders are among the most disabling medical conditions worldwide and currently available treatments fall short of addressing this large public health burden. Dysfunction within the brain reward system is …
Baylor Role:
Collaborator
Completed
Telehealth Depression Treatments for Older Adults (External Link)
The long-term objective of the proposed study is to improve access to depression treatments for low-income, racially diverse homebound seniors, a population experiencing significant disparities in mental health care due …
Baylor Role:
Collaborator
Completed
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) (External Link)
The primary objective is to investigate whether all doses (0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, and 1.0 mg/kg) of ketamine are superior to active placebo (midazolam 0.045 mg/kg) therapy in …
Baylor Role:
Collaborator
Completed
One-Day Intervention for Depression and Impairment in Migraine Patients (External Link)
Adults with comorbid depression and migraine will be randomized to a 1-day (6-hour) workshop of Acceptance and Commitment Training + Migraine Education (ACT-ME) or Migraine Education only (MEO). The intervention …
Baylor Role:
Lead Sponsor
Completed
Optimization of IV Ketamine for Treatment Resistant Depression (External Link)
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a …
Baylor Role:
Lead Sponsor
Completed
Expressive Writing for Co-Occurring Depression and Alcohol Misuse (External Link)
Expressive writing applied to a variety of populations (e.g., HIV, cancer, PTSD, depression) has been associated with health improvements, reductions in symptoms of emotional distress, and one preliminary study found …
Baylor Role:
Lead Sponsor
Completed
Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury (External Link)
Traumatic brain injury (TBI) is a leading cause of death and disability among young adults. Mood disorders are the most frequent psychiatric complication of TBI, and have a large impact …
Baylor Role:
Lead Sponsor
Completed
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications (External Link)
This research proposal will investigate a glutamate-modulating agent, riluzole, in treatment-resistant patients who exhibit an acute, sustained response to a single dose of intravenous (IV) racemic ketamine. Fifty ketamine-responders will …
Baylor Role:
Lead Sponsor